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Background: The present pharmacoeconomic study compared the direct and indirect costs of using frovatriptan
versus rizatriptan in the acute treatment of migraine.
Methods: Data on the cost-efficacy of the two triptans were derived from a recently published Italian, multicenter,
randomized, double-blind, cross-over patient preference study, comparing frovatriptan versus rizatriptan. The direct
costs were obtained by calculating the drug consumption, both of triptans and rescue medications. Prices of
currently marketed drugs were obtained from Italian Drug Agency price list. The indirect costs were those related
to absenteeism from the workplace due to migraine.
Results: 129 of the 148 patients with a current history of migraine randomized to the two study drugs and
completing the study were analyzed. The number of attacks treated with only 1 dose of study drug was higher
with frovatriptan (157 vs. 147), whereas the number of attacks treated with ≥2 doses of study medication was
higher with rizatriptan (122 vs. 110 and 74 vs. 67, respectively). However, more patients treated with frovatriptan
took a rescue medication (71 vs. 59). The total direct cost per attack (including study drug rescue medication) was
9.12 € for frovatriptan and 13.54 € for rizatriptan (p < 0.05 between-treatments). As for indirect costs, in the group of
patients treated with frovatriptan the mean number of lost working hours was significantly (p < 0.05) lower (1.5 h)
compared to the subjects who used rizatriptan (2.8 h). Based on the earned income per unit of work, indirect costs
per attack resulted to be 24.55 € for frovatriptan and 45.84 € for rizatriptan. Overall, the total costs, including direct
and indirect costs, were evaluated to be 33.67 € for frovatriptan and 59.38 € for rizatriptan, respectively.
Conclusions: Within the limitations of this model analysis, frovatriptan was found to be significantly more
cost-effective than rizatriptan. This outcome can be explained by the lower acquisition cost of frovatriptan, the need
for fewer doses, and the loss of fewer working hours. This finding could drive selection of the most appropriate oral
treatment for acute migraine attacks based on both individual patient’s needs and the cost-effectiveness of the
available drugs.
Trial registration: 2006-002572-17 (EudraCT).
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Migraine is a common, chronic, neurovascular disorder
characterized by recurrent attacks of headache and asso-
ciated symptoms. Studies conducted around the world
have consistently shown that migraine affects approxi-
mately 12–15% of the general adult population. This dis-
order is widespread across the world, mostly affecting
young and middle-aged people, and is two-to three-* Correspondence: carlo.lisotto@aopn.sanita.fvg.it
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in any medium, provided the original work is ptimes more common in women than in men [1,2]. Mi-
graine patients differ in their management needs, largely
due to the variation in severity of symptoms and their
impact on the sufferer. Acute medications are needed by
all migraineurs for symptomatic treatment and, for the
majority of patients who have infrequent attacks, are the
only therapy required. The migraine-specific medica-
tions that have become known as the triptans have revo-
lutionized the acute treatment of migraine headache
during the past 20 years. Triptans are the first-choice
drugs for moderate-to-severe migraine attacks in all then Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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including the USA, UK, Italy, Canada, Germany and
France. Triptans are selective 5-HT1B and 5-HT1D re-
ceptor agonists. Seven oral triptan formulations are now
available for the treatment of migraine, each with its
own characteristic strengths over a range of treatment
attributes. Frovatriptan is the newest addition to the
triptan class: its mean half-life is 26 h, the longest in the
triptan group. The molecule was selected for develop-
ment based upon its distinctive pharmacologic charac-
teristics, which suggested that it would have the clinical
potential for a long duration of action [3-5], and a low
likelihood of side effects [6,7] and drug interactions
[3,4,8,9]. This therapeutic profile makes this triptan par-
ticularly suitable for treating patients whose migraine at-
tacks last a long time, with an associated high risk of
headache recurrence. In the new guidelines for con-
trolled trials of drugs in migraine established by the
International Headache Society (IHS), relapse (recur-
rence) is deemed to be a major problem with all effective
migraine treatments and should be recorded as an im-
portant efficacy index [10]. Recent trials have confirmed
that frovatriptan has the lowest recurrence rate, when
compared to other triptans [6]. Moreover, due to its pro-
longed duration of action, frovatriptan provides a higher
sustained pain response [11-13]. Triptans have shown to
be highly effective, well tolerated and the most cost-
effective migraine therapy in patients with severe symp-
toms and disability [14]. In head to head comparative
trials the patients’ preference for one triptan or the other
was not linked to pain-free rates. The drugs showed
similar efficacy in the short-term, but frovatriptan seems
to be unique in the triptan class, having the longest dur-
ation of action and the lowest recurrence rate [7,15,16].
The good long-term efficacy of frovatriptan supports its
indication for those patients requiring a prolonged dur-
ation of action, with a sustained effect and less side ef-
fects [5-7,15]. Rizatriptan is one of the most widely used
triptans for the acute treatment of migraine. A system-
atic review and meta-analysis of the available triptans
conducted in 2001, evaluating 53 double-blind, random-
ized, placebo-controlled trials, showed rizatriptan to be
associated with the highest 2-h pain-free rates [17]. Riza-
triptan is rapidly absorbed after oral administration; the
bioavailability is approximately 40-45% and Tmax is
about 1–1.5 hours [18].
The costs due to migraine (episodic and chronic) have
been reported in several papers. The impact of migraine is
a problem of enormous proportion, both for individual sub-
jects and society [19]. The total indirect costs were calcu-
lated to be 1.1 billion $ per year in the US and more than 3
billion € per year in Europe [20-24]. Comparisons between
triptan treatments, in terms of the cost to treat a single at-
tack, were appraised in some European Countries. Whereasin France no difference between cost-efficacy of rizatriptan
and frovatriptan was noted, in other three European Coun-
tries (Italy, Germany and UK) frovatriptan was shown to be
associated with a lower cost per attack, with a significantly
lower intake of rescue medications in the 24 hours follow-
ing the triptan first dose [25-28]. The aim of this study was
to compare direct and indirect costs for frovatriptan com-
pared with rizatriptan in the acute treatment of migraine,
based on the patients’ preference for one or the other of
the comparative drugs.
Methods
The cost analysis of drugs was conducted through a
structured decision tree, built up taking into account the
National Healthcare System perspective. Data on the
cost-effectiveness of drugs and the direct and indirect
costs were derived from a clinical study by Savi et al.
[15].
Study population
The subjects eligible for participation in the study were
adults ≥18 and ≤65 years of age with a current history of
migraine with or without aura according to the Inter-
national Classification of Headache Disorders – second edi-
tion (ICHD-II), with at least one episode per month during
the last 6 months prior to entering the study. Individuals
with any contraindication to triptans or any severe or disab-
ling medical condition (such as uncontrolled hypertension
and cardiac, vascular or severe liver or renal impairment)
could not be enrolled. Subjects were also excluded if they
had a history of alcohol, analgesic or psychotropic drug
abuse, a known hypersensitivity to the study drugs, a previ-
ous inadequate response to at least two triptans, and if they
were currently using ergotamine or MAO-inhibitors, or
had tension-type headache on more than six days per
month. Pregnant women, breastfeeding mothers, and
women of childbearing age with a positive or missing preg-
nancy test were not eligible. The study protocol and in-
formed consent form were reviewed and approved by the
independent institutional review board of each participating
institution. Written informed consent was obtained for
each subject.
Study design
This was a multicenter, randomized, double-blind, cross-
over study, conducted in 15 centers across Italy. Each pa-
tient received the two comparative study treatments in se-
quence, being the sequence determined by randomization.
After having treated 3 episodes of migraine in not more
than 3 months with the first treatment, the patient was
switched to the other treatment. After having treated 3 epi-
sodes of migraine in not more than 3 months with the sec-
ond treatment, the patient was requested to indicate the
preference for the first or second treatment, on a visual
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was to evaluate the average strength of preference
expressed by the patient on the visual analogue scale for
the first or second treatment received. Furthermore pa-
tients completed Migraine Disability Assessment Scale
(MIDAS) and Personal Preferences Questionnaire (PPQ).
The details of the trial methods and all the results (primary
and secondary endpoints) are reported elsewhere [15].
Treatment
The subjects were recommended to take the first dose of
study medication as early as possible after the onset of
migraine attack. In case of unsatisfactory or none re-
sponse after two hours, a second dose of study medica-
tion was allowed. If the relief was still insufficient, the
patients could take the rescue medication (triptans and
ergot derivatives excluded) one hour after the second
dose. Patients who used triptans as rescue medications
were excluded from the per protocol analysis and were
included in the intention-to-treat analysis.
Pharmacoeconomic data
Direct costs
Direct costs include all of the costs of diagnosing and treat-
ing a disease. In the case of migraine, this includes health
care utilization figures such as rates of outpatient visits,
hospitalization, the use of emergency department services,
and costs of prescriptions. The latter were taken into ac-
count to the purpose of this survey. The analysis was per-
formed in accordance with the published Italian guidelines
[29,30]. The straightforward economic quantification of dir-
ect costs was represented by the drug consumption, both of
triptans and rescue medications. The fixed or defined daily
dose (DDD) is the recommended daily dose of the drug in
the adult population. This dose is 2.5 mg for frovatriptan
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Figure 1 Study design.calculated multiplying the number of DDDs taken in the
two study arms by the corresponding DDD cost. Prices of
currently marketed drugs were obtained from Italian Drug
Agency price list [33].
Indirect costs
Indirect costs include the aggregate effects of migraine on
productivity at work, and in other roles. Many migraine
sufferers miss work because of their headaches, and re-
duced productivity as a result of working during a migraine
is common. Loss of productivity can be assessed measuring
how much time patients have lost on workplace for their
usual activities. Using a human capital approach, indirect
costs can be expressed as costs incurred due to absenteeism
from the work place. To determine the cost related to a lost
working day, the average Italian yearly salary, i.e. 28,811.20
€ [34], was divided by the mean number of working days
per year, which in Italy is 220. The average cost per day
thus was estimated to be € 130.96. A typical working day
includes 8 productive hours.
Data analysis
Results are reported using proportions for categorical data,
mean as central tendency parameters for continuous data
and standard deviation (SD) value as dispersion parameters.
Costs were reported as mean €/migraine attack. In order to
compare results obtained from the two study arms, a t-test
was used and p-values lower than 0.05 were kept for statis-
tical significance. All analyses were performed using Statis-
tical Analysis System (SAS 9.2).
Results
Study population
A total of 148 patients with a current history of migraine
were screened and randomized to the two study groups.
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Figure 2 Flow diagram of participants throughout the main study.
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Table 1 Demographics and clinical data of the intention-
to-treat (ITT) population [13]
ITT (N = 125)
Age (years, mean ± SD) 37 ± 9
Females (n, %) 99 (79)
Height (cm, mean ± SD) 167 ± 9
Weight (kg, mean ± SD) 64 ± 13
Age at onset of migraine (years, mean ± SD) 16 ± 7
Migraine with aura (n, %) 4 (3)
MIDAS score (mean ± SD) 22 ± 15
Migraine attack duration >2 days (n, %) 26 (21)
Data are shown as mean (±SD), or absolute (n) and relative frequency (%).
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both trial periods. Nineteen patients withdrew from the
study for the following reasons: dissatisfaction to
assigned treatment (n = 1), withdrawal of consent (n = 6),
failure to treat one episode of migraine (n = 6), occur-
rence of an adverse event (n = 2), protocol violation
(n = 1), deterioration of target disease symptoms (n = 1),Table 2 Rescue medication list
Cross-over
Frovatript























*Patients who used triptans as rescue medications were excluded from the per proor other reasons (n = 2). Patients considered valid for the
economic evaluation were the intention-to-treat popula-
tion, which included 125 subjects [15].
Main study’s results
No significant differences in terms of preference scores
were found between the two study medications (3.2 ± 1.1
for rizatriptan vs. 2.9 ± 1.3 for frovatriptan). The patients
who have expressed their preference for frovatriptan re-
ported as main factors for their choice: rapidity of action
(71%), tolerability (42%), reduction in pain severity
(33%), complete analgesia (33%) and functional recovery
(33%). The patients’ reasons for preferring rizatriptan
were: rapidity of action (66%), reduction in pain severity
(54%), complete analgesia (54%), tolerability (38%) and
functional recovery (36%). The most relevant finding
resulting from the study was the significantly lower re-
currence rate within 48 h for frovatriptan (21%) vs. riza-
triptan (43%); this difference was statistically significant
(p < 0.001). Table 1 summarizes clinical and demo-
graphic data of the intention-to-treat population.study arm Total
an Rizatriptan











































Figure 3 Direct (full bars) and indirect (open bars) costs per
migraine attack. Total costs are reported on top of each bar.
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Patients were treated with 1 or 2 doses of study medica-
tions per attack, either oral frovatriptan 2.5 mg or oral
rizatriptan 10 mg; these formulations correspond with
the DDD dosages [33].
Patients were allowed to take a rescue medication if the
study treatment could not abort the migraine attack within
3 hours of its onset, one hour after the possible second dose
of the study drug. During the 6-month study period, 719
migraine episodes were recorded, 357 in the frovatriptan
arm and 362 in the rizatriptan arm [15]. The number of at-
tacks and the number of medications used to treat the at-
tacks in each arm of the cross-over study are illustrated in
Table 2.
Taking into account only the triptan use, the cost for
treating migraines was 3,170 € for frovatriptan (357 at-
tacks) and 4,782 for rizatriptan (362 attacks).
One hundred and thirty of the 719 triptan-treated mi-
graine attacks required the use of rescue medication
(further triptans and ergot derivatives were excluded by
protocol). Rescue medication was taken by 19.9% of sub-
jects in frovatriptan arm and by 16.3% of patients in
rizatriptan arm. A list of all active compounds used as
rescue medication in either arm is shown in Table 2.
The most commonly used rescue medications were non-
steroidal anti-inflammatory drugs, in particular:
 Salicylates, 2.8% in frovatriptan arm and 0% in
rizatriptan arm;
 Propionic acid derivatives, 36.2% in frovatriptan arm
and 36.5% in rizatriptan arm
 Acetic acid derivatives, 44.8% in frovatriptan arm
and 11.5% in rizatriptan arm
 Enolic acid (Oxicam) derivatives, 2.8% in
frovatriptan arm and 2.1% in rizatriptan arm;
 Selective COX inhibitors, 12% in frovatriptan arm
and 5.2% in rizatriptan arm
 Sulphonanilides, 19.4% in frovatriptan arm and 15.6
in rizatriptan arm;
 Others, 13.8% in frovatriptan arm and 13.5% in
rizatriptan arm
Other rescue medications used were: antiemetics
(1.0% in frovatriptan arm and 3.6% in rizatriptan arm)
and corticosteroids (1.0% frovatriptan arm; 0% riza-
triptan arm). The total cost of rescue medications
was 85.7 € for the patients who used frovatriptan and
119.46 € for the subjects treated with rizatriptan. The
total direct costs, consequently, were expressed add-
ing the study drug treatment and the rescue medica-
tion costs together.
The total cost per attack was calculated to be 9.12 € for
frovatriptan (0.24 € for rescue medication) and 13.54 € for
rizatriptan (0.33 € for rescue medicine).Indirect cost
Treatment with frovatriptan also had a positive impact
on the magnitude of working hours lost due to migraine
attacks. In the group of patients treated with frovatriptan
the mean number of lost working hours was significantly
(p < 0.05) lower (1.5 h) compared to the subjects who
used rizatriptan (2.8 h).
Evaluating the average loss of productivity [15] and the
earned income per unit of work [34], applied to the
number of migraine attacks observed during the study,
the costs due to lost working days in the two treatment
groups were estimated to amount to 8,766.13 € for fro-
vatriptan (357 attacks) and 16,592.63 € for rizatriptan
(362 attacks). Indirect costs per attack were 24.55 € for
frovatriptan and 45.84 € for rizatriptan.
Total costs
Overall, total costs, including direct and indirect costs,
were evaluated to be 33.67 € for frovatriptan and 59.38 €
for rizatriptan, respectively, as shown in Figure 3.
Discussion
Triptans ushered in a new era in acute migraine therapy,
with their ability to provide rapid relief of headache and
associated symptoms. With the introduction of triptans,
migraine therapy has made a quantum leap forward
[11]. Triptans are currently the first line drugs for the
acute treatment of migraine [14] as they have revolu-
tionized the management of this disorder. Since the
introduction of the first triptan, sumatriptan, launched
over 20 years ago, six other triptans with distinctive
pharmacokinetic properties have been developed [11].
Although all triptans have the same mechanism of ac-
tion and simple and consistent pharmacokinetic features,
there are specific differences among individual agents
that may account for their different clinical attributes.
For instance, in the treatment of perimenstrual mi-
graines, which are known to be particularly severe and
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of efficacy, either given for acute attacks or for short-
term prophylaxis [35]. In the patient preference head to
head comparative trials, the drugs showed similar effi-
cacy in the short-term, in particular at 2 hours, but fro-
vatriptan provided a more sustained response, with a
lower recurrence rate, likely related to its much longer
elimination half-life [6]. The pooled systematic analysis
of the three preference trials conducted in Italy suggests
that frovatriptan has a similar antimigraine efficacy to
other widely employed triptans (rizatriptan, zolmitriptan
and almotriptan). This is true of both the immediate and
the sustained pain-relieving effects. Frovatriptan has also
been shown to be better tolerated than the other studied
triptans [6].
In this pharmacoeconomic study frovatriptan treatment
has shown to be less expensive than rizatriptan, despite the
slightly higher number of rescue medication doses required.
This outcome can be explained by a combination of the
lower number of doses needed, on average, to treat a mi-
graine attack, and the lower number of hours lost from the
workplace when using frovatriptan.
There are two important limitations of this study: first
of all, that this is not a pharmacoeconomic study, but a
sub-analysis not provided in statistical plan and secondly
this analysis was based on the human capital approach.
This approach suggests that health care interventions
are a kind of investment in an individual’s human capital
(similar to education). According to this method, evalu-
ation of productivity losses is based on labor costs. All
future productivity losses (up to retirement age) are con-
sidered in the human capital approach, but obviously it
represent a selection of costs included in the model, so
some other costs aren’t included.Conclusions
On the basis of published data [23,29] and with the
model analysis based on the human capital approach, re-
sults suggest the economical advantage of frovatriptan
2.5 mg among the oral triptans approved for the treat-
ment of migraine in Italy. In this study, in particular, fro-
vatriptan was found to be significantly more cost-
effective than rizatriptan. This outcome can be explained
by the lower acquisition cost of frovatriptan, the need
for fewer doses, and the loss of fewer working hours.
This finding could drive selection of the most appropri-
ate oral treatment for acute migraine attacks, based on
both individual patient’s needs and the cost-effectiveness
of the available drugs.
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